Skip to main content
. 2019 Aug 24;20(17):4136. doi: 10.3390/ijms20174136

Table 3.

Novel agents targeting microenvironment components that achieve clinical benefits in combination with a cisplatin-containing regimen.

Drug Category Major target Clinical benefit Reference
Bevacizumab Angiogenesis antagonist Vascular endothelial growth factor A 1. In the AVAil study, combination therapy (cisplatin, gemcitabine plus bevacizumab) prolonged PFS (HR = 0.82; p = 0.03) in first-line therapy for patients with advanced nonsquamous nonsmall-cell lung cancer compared with the control group (cisplatin plus gemcitabine).
2. In the AVAPERL study, combination therapy (cisplatin, pemetrexed plus bevacizumab) prolonged PFS (HR = 0.48; p < 0.001) in first-line therapy for patients with advanced nonsquamous nonsmall-cell lung cancer compared with the control group (cisplatin plus pemetrexed).
[84,85]
Pembrolizumab Immune check point inhibitor Programmed cell death protein 1 In the KEYNOTE-189 study, combination therapy (cisplatin, pemetrexed plus pembrolizumab) increased OS at 12 months (HR = 0.49; p < 0.001) in first-line therapy for patients with advanced nonsmall-cell lung cancer compared with the control group (cisplatin plus pemetrexed). [101]

PRS: progression-free survival, HR: hazard ratio, OS: overall survival.